obinutuzumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
obinutuzumab

GtoPdb Ligand ID: 6941

Synonyms: GA-101 | GA101 | Gazyva®

obinutuzumab is an approved drug (FDA (2013), EMA (2014))

Compound class: Antibody

Comment: Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

View more information in the IUPHAR Pharmacology Education Project: obinutuzumab

References
1. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA et al.. (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood, 117 (17): 4519-29. [PMID:21378274]
2. Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, Fragoso-Loyo H, Zuta-Santillan E, Schindler T, Brunetta P et al.. (2022) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis, 81 (1): 100-107. [PMID:34615636]
3. Genentech Media. FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis. Accessed on 25/09/2019. Modified on 25/09/2019. Genentech, https://www.gene.com/media/press-releases/14811/2019-09-17/fda-grants-breakthrough-therapy-designat?elqTrackId=8dd752c5464246d2864338e62ba78820&elq=7aed654c4c2d4934a203067e44937351&elqaid=26161&elqat=1&elqCampaignId=10601
4. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther, 12 (10): 2031-42. [PMID:23873847]
5. Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. (2014) Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma, 55 (1): 188-90. [PMID:23537278]
6. Rovin BH, Furie RA, Ross Terres JA, Giang S, Schindler T, Turchetta A, Garg JP, Pendergraft 3rd WF, Malvar A. (2024) Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial. Arthritis Rheumatol, 76 (2): 247-254. [PMID:37947366]

References

1. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA et al.. (2011)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Blood, 117 (17): 4519-29. [PMID:21378274]

2. Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, Fragoso-Loyo H, Zuta-Santillan E, Schindler T, Brunetta P et al.. (2022)
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
Ann Rheum Dis, 81 (1): 100-107. [PMID:34615636]

3. Genentech Media.
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis.
Accessed on 25/09/2019. Modified on 25/09/2019. Genentech, https://www.gene.com/media/press-releases/14811/2019-09-17/fda-grants-breakthrough-therapy-designat?elqTrackId=8dd752c5464246d2864338e62ba78820&elq=7aed654c4c2d4934a203067e44937351&elqaid=26161&elqat=1&elqCampaignId=10601

4. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013)
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Mol Cancer Ther, 12 (10): 2031-42. [PMID:23873847]

5. Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. (2014)
Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab.
Leuk Lymphoma, 55 (1): 188-90. [PMID:23537278]

6. Rovin BH, Furie RA, Ross Terres JA, Giang S, Schindler T, Turchetta A, Garg JP, Pendergraft 3rd WF, Malvar A. (2024)
Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial.
Arthritis Rheumatol, 76 (2): 247-254. [PMID:37947366]